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Abstract: IBMPFD/ALS is a genetic disorder caused by a single amino acid mutation on the p97
ATPase, promoting ATPase activity and cofactor dysregulation. The disease mechanism underlying
p97 ATPase malfunction remains unclear. To understand how the mutation alters the ATPase
regulation, we assembled a full-length p97R155H with its p47 cofactor and first visualized their
structures using single-particle cryo-EM. More than one-third of the population was the dodecameric
form. Nucleotide presence dissociates the dodecamer into two hexamers for its highly elevated
function. The N-domains of the p97R155H mutant all show up configurations in ADP- or ATPγS-
bound states. Our functional and structural analyses showed that the p47 binding is likely to impact
the p97R155H ATPase activities via changing the conformations of arginine fingers. These functional
and structural analyses underline the ATPase dysregulation with the miscommunication between
the functional modules of the p97R155H.
Keywords: p97 ATPase; p97R155H mutation; p47 cofactor; arginine finger; IBMPFD; single-particle
cryo-EM
1. Introduction
Human p97/VCP (valosin-containing protein) belongs to the type II AAA+ (ATPase
Associated with various cellular Activities) protein family, which has two AAA+ ATPase
domains [1,2]. The orthologs are known as Cdc48 in Saccharomyces cerevisiae and transitional
endoplasmic reticulum (TER) ATPase in archaebacteria and eukaryotes. p97 acts as a
molecular hub, interacting with various cofactors to perform a wide variety of cellular
functions, including autophagy, cell-cycle regulation, ubiquitin-dependent proteostasis,
and reassembly of Golgi and nuclear membranes [3–7]. p97 is abundant in the cytosol,
comprising 1% of the cytosolic proteins [8,9], and carries out ATP hydrolysis to gain energy
to fuel the conformational change underlying its activities [10–13]. Abnormal functions or
uncontrolled regulations of p97 can cause serious diseases. Single amino acid mutations
in human p97 have been linked to diseases of aging and neurodegeneration, including
IBMPFD (inclusion body myopathy with Paget’s disease of bone and frontotemporal
dementia) and familial amyotrophic lateral sclerosis (ALS) [14–17].
p97 comprises an N-terminal domain (NTD), two ATPase domains, D1 and D2, con-
taining conserved Walker A and B motifs, and an unstructured C-terminal tail [2]. The
NTD and C-terminal tail are the key domains regulating ATPase function [10,13,18,19].
Six p97 monomers form a functional complex, featuring a double-ring structure based
on the association of D1 and D2. The D1 domain is responsible for p97 oligomerization,
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regardless of their nucleotide-binding states. Upon ATP binding to the D1 domain [20–22],
the D2 domain is the primary mediator of ATP hydrolysis [21,23–27]. The two stacked
rings create a central channel in the p97 hexamer that binds substrates, facilitating the
segregation of substrates destined for proteolysis from their usual location in multi-subunit
complexes, organellar membranes, and chromatins [28,29]. Previous cryogenic electron
microscopic (cryo-EM) structures of the AAA+ ATPases revealed that the substrate process-
ing by the Cdc48 ATPase results in a broken ring and an asymmetric structure of the six
p97 monomers. These structures have been used to suggest a hand-over-hand model for
the substrate’s induced motion [30–32]. The substrate movement along the central channel
is dependent on the D1 nucleotide state and is mainly driven by the ATP hydrolysis on the
D2 domain [33,34]. This movement would call for cooperation between domains within the
AAA+ ATPase complex and cofactor bindings [10,35,36]. However, it is not certain whether
the hand-over-hand model applies to other p97 functions, such as membrane fusion.
The p97 NTD mediates the binding of various cofactors and ubiquitylated substrates
and modulates ATPase activity [13,19]. Although the p97 NTD does not directly relate to
nucleotide binding, it has two distinct configurations that are affected by the D1 nucleotide-
binding states: the ‘up’ (ATP-bound D1) configuration, rising above the plane of the D1
ring, and the ‘down’ (ADP-bound D1) configuration, coplanar with the D1 ring [26,27,37].
However, previous EM structural analysis revealed variant NTD positions, rather than the
only two distinct states [19,38]. One hypothesis suggests that the NTD configuration affects
linker conformation, initiating inter-subunit or intra-domain communication, thus influ-
encing ATPase activity [39–41]. This is supported by the position of IBMPFD-associated
disease mutants that result in elevated ATPase activities, mostly from the D2 ATPase [19,42].
The IBMPFD mutations cluster on the NTD or the N-D1 linker of the p97 [26,43]. Because
the mutation sites are far away from the D2 nucleotide-binding site, it has been suggested
that the NTD mutation changes the interactions between p97 inter-domains, leading to
functional alterations [34]. However, the connection between the pathological effects of the
IBMPFD mutations and elevated p97 ATPase activity remains unclear.
In addition to mutations, the binding of p97 cofactors on the NTDs also impacts
ATPase activities. p47 is one of the p97 cofactors involved in p97-mediated membrane
fusion [7]. It contains an N-terminal UBA (ubiquitin-associated) domain, followed by a SEP
(shp1, eyc, and p47) and UBX (ubiquitin-regulatory X) domain, which interacts with the
p97 NTD (Figure 1A) [24,40,44]. The interaction reduces the D1 ATPase activities of both
wild-type and p97 mutants [45]. Also, p47 enhances the D2 ATPase activity of wild-type
p97 (p97WT), whereas it reduces the activities of the p97 disease mutants [45]. Thus, p47
has different effects on the two ATPase domains of both p97WT and its mutants, resulting
in that the mutant p97-p47 complex blocks the ATP hydrolysis in one single sigmoidal
phase, rather than a biphasic response of the wild-type p97-p47 complex [45].
The binding mode of the p47 UBX domain to the p97 NTD is conserved among
the UBX or UBX-like (UBX-L) containing cofactors [46]. Previous structures of partial
or complete complexes reveal this interaction as seen in p97N-D1-p47UBX, p97N-FAF1UBX,
p97N-OTU1UBXL, and p97-ASPL [24,47–51]. The high-resolution crystal structure of the
p97N-D1-p47UBX truncated complex showed that a conserved β sheet with an S3/S4 loop
in the UBX domain binds to a hydrophobic pocket formed by the two p97 N-subdomains
(comprised of an Na (four-stranded β barrel) and an Nb (ψ barrel) domain) [24]. Recently,
the bipartite and tripartite binding modes have been proposed for the interactions between
multiple p47 and wild type p97 NTDs [51]. However, how this binding in the combination
of disease NTD mutations modulates the D1 and D2 ATPase activities remain uncertain.
Most of the current data for p97 mutants were based on the structures of truncated do-
mains [52]. Because the structural information of the full-length diseased complexes is still
lacking, more efforts on studying their functions and structures are needed to understand
the mechanistic details.
Int. J. Mol. Sci. 2021, 22, 8079 3 of 21
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 3 of 21 
 
 
[52]. Because the structural information of the full-length diseased complexes is still lack-
ing, more efforts on studying their functions and structures are needed to understand the 
mechanistic details. 
 
Figure 1. Characterization of the p97R155H-p47 and p97WT-p47 complex formation. (A) Domain 
structures of the p97 ATPase and its cofactor p47. The disease-linked mutation of R155H is labeled 
on the NTD of p97. (B) Size-exclusion chromatographic (SEC) profiles of the p97WT-p47 (left) and 
p97R155H-p47 (right) assemblies. Blue and purple curves are for the p97-p47 assembly and p47 protein 
alone. Peak fractions are labeled. (C) SDS-PAGE analysis of the SEC eluted peaks of the p97-p47 
assemblies. (D) Determination of dissociation constants, Kd, for the p97WT-p47 and p97R155H-p47 com-
plexes. Unlabeled p97 was titrated against 10 nM of RED-NHS-labeled p47 in two-fold steps from 
2.80 µM to 1.37 nM. The temperature-related intensity change (TRIC) signals were recorded and 
plotted against p47 concentrations. 
Here we performed functional and structural analyses on the disease-linked com-
plex, p97R155H-p47, to understand how the cofactor binding and NTD mutation leads to 
functional alterations. We chose p97R155H as our target, since the NTD mutation of arginine 
155 to histidine (R155H) is the most commonly found in the IBMPFD phenotype [53]. We 
have previously identified that p97 disease mutants are defective in the cofactor-regulated 
ATPase hydrolysis cycle [45]. Also, the increased p47 expression can correct the 
Figure 1. Characterization of the p97R155H-p47 and p97WT-p47 complex formation. (A) Domain
str ctures of the p97 ATPase and its cofactor p47. The disease-linked mutation of R155H is labeled
on the NTD of p97. (B) Size-exclusion chromatographic (SEC) profiles of the p97WT-p47 (left) and
p97R155H-p47 (right) assemblies. Blue and purple curves are for the p97-p47 assembly and p47 protein
alone. Peak fractions are labeled. (C) SDS-PAGE analysis of the SEC eluted peaks of the p97-p47
assemblies. (D) Determination of dissociation constants, Kd, for the p97WT-p47 and p97R155H-p47
complexes. Unlabeled p97 was titrated against 10 nM of RED-NHS-labeled p47 in two-fold steps
from 2.80 µM to 1.37 nM. The temperature-related intensity change (TRIC) signals were recorded
and plotted against p47 concentrations.
Here we performed functional and structural analyses on the disease-linked complex,
p97R155H-p47, to understand how the cofactor binding and NTD mutation leads to func-
tional alterations. We chose p97R155H as our target, since the NTD mutation of arginine
155 to histidine (R155H) is the most commonly found in the IBMPFD phenotype [53]. We
have previously identified that p97 disease mutants are defective in the cofactor-regulated
ATPase hydrolysis cycle [45]. Also, the increased p47 expression can correct the autophagy
defect caused by the p97 disease mutant [45]. To understand how p47 impacts the function
of the p97R155H disease mutant, we characterized the interactions between the p97R155H and
p47 using single-particle cryo-EM image analysis. The structural results revealed two major
forms in the molecular population: the p97R155H dodecamer and the p97R155H hexamer-p47
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complex. The nucleotide-binding pockets are empty in the p97R155H dodecamer. The
presence of the nucleotides, such as ADP or ATPγS, destabilizes the dodecameric forma-
tion. The NTDs showed all up configurations when bound to ATPγS or in the absence
of nucleotides. However, in the presence of ADP, the NTDs of the mutant allow variable
intermediate positions, which may affect the accessibility of the p47 cofactor. Our structures
also showed that the arginine fingers exhibit different conformations than those of the wild
type when p97R155H binds to p47. We propose a possible model that impacts functional
alteration of the p97R155H upon p47 binding, providing an insight into the pathological
function of the IBMPFD-associated p97 mutants.
2. Results
2.1. Two Molecular Populations Are in the p97R155H-p47 Assembly
To analyze the activity of mutated p97, we first assembled an in vitro complex of
full-length p97R155H with p47 in the absence of nucleotides (molar ratio of p97R155H hex-
amer:p47 monomer 1:10). A peak representing the p97R155H-p47 complex, corresponding
to a molecular weight of about 670 kDa, was detected in the size-exclusion chromato-
graphic (SEC) profile (Figure 1B). The peak profile showed a leading shoulder, implying
that multiple molecular species were present in the peak fraction. We further character-
ized the peak fractions using SDS-PAGE, which confirmed the presence of both p97R155H
and p47 proteins in the main peak fraction and only the p97R155H proteins in the leading
shoulder (Figure 1C). This observation corroborates the previous report on the IBMPFD
mutants, which showed that a full-length p97R155H dodecamer was present in the leading
fraction [19]. In contrast, the p97WT-p47 assembly did not show an asymmetric leading
peak profile (Figure 1B). Thus, the p97R155H mutant is found in additional forms, forming
complexes beyond the hexameric arrangement of the wild-type protein. Although the
higher-order form has been reported for the wild type [19], inhibitor-bound [54,55], or
engineered p97 [56], we did not find the same pattern in the SEC of the wild type, possibly
because the high-order complex was in a less proportion in the wild type that could not be
detected. In the SDS-PAGE analysis, these higher-order complexes do not associate with
p47, even in the presence of excess p47 (Figure 1B). This suggests that the higher-order
arrangement of p97R155H may hinder the interaction with the p47 cofactor.
If the high order p97R155H does not interact with p47 and forms in a larger proportion
than the wild type, the p47 binding affinity to the p97R155H on average is lower than
that of the wild type p97WT. To test this idea, we further employed fluorescent labeling
and measured the temperature-related intensity change (TRIC) signal to determine the
affinities of the p47 binding on p97WT and p97R155H and their dissociation constants, Kd. In
the absence of nucleotides, the resulting Kd averages of p97WT-p47 and p97R155H-p47 are
80 nM and 132 nM, respectively, suggesting a slightly higher binding affinity for the wild
type (Figure 1D).
2.2. Up NTDs of the p97R155H Mutant and p47 Are Structurally Disordered
To visualize the interaction between the p97R155H mutant and the p47 cofactor, we
plunge-froze the sample of the p97R155H-p47 assembly for single-particle cryo-EM analysis.
Notably, two different particle populations were discernible in the two-dimensional (2D)
class averages (Figure S1A). One showed a typical side view of the p97 hexameric form,
and the other showed two stacked p97 hexameric double rings (Figure S1A). Ab initio map
generation produced two different three-dimensional (3D) densities presenting one with
general p97 hexameric features and the other containing a dimer of hexamers (Figure S1B).
We reconstructed the 3D density maps of the p97R155H dodecamer complex at 3.34 Å
resolution and the p97R155H-p47 complex at 4.30 Å (Figure 2 and Figure S1B,C). The ratio
of the single-particle images of the p97R155H-p47 complex to the p97R155H dodecamer is
1.56:1.
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S2D). For p97R155H dodecamer, we did not find densities that could be assigned to p47. 
Based on specific map features of the p97R155H-p47 complex, we were able to identify the 
NTD and p47UBX domains at a lower contour level (2.7σ) by docking available atomic mod-
els (PDB code: 1S3S) into the density map (Figure 2B) [24]. Four NTD densities could be 
assigned and shown in up configurations, and they are rendered into slightly different 
orientations in the azimuthal direction along the C6 pseudo-symmetrical axis (Figure 2B). 
Only one p47UBX domain was found to fit into the density attached to the up NTD (Figure 
Figure 2. Cryo-EM reconstructions of the p97R155H dodecamer and the p97R155H-p47 complex. Cryo-
EM densities of (A) p97R155H dodecamer (5.6σ) and (B) p97R155H-p47 complex (2.3σ). Green, orange,
orange-red, and yellow highlight the NTD, D1, and D2 of the p97R155H and p47UBX, respectively.
Grey color indicates regions where densities could not be assigned. Envelopes are the cryo-EM
maps at a lower contour (p97R155H dodecamer: 2.4σ; p97R155H-p47: 1.6σ). (C) UMAP (uniform
manifold approximation and projection) representation of a generative neural network analysis of
the p97R155H-p47 cryo-EM density. Blue intensities represent the distribution of particle images in the
embedded latent space. Three different 3D averages (brown, green and light orange) were calculated
from the chosen clusters (orange circles).
Local resolution estimation showed that the density of the p97R155H dodecamer or
the p97R155H-p47 complex is well resolved in D1 and D2 domains but not the NTDs
(Figure S2D). For p97R155H dodecamer, we did not find densities that could be assigned
to p47. Based on specific map features of the p97R155H-p47 complex, we were able to
identify the NTD and p47UBX domains at a lower contour level (2.7σ) by docking avail-
able atomic models (PDB code: 1S3S) into the density map (Figure 2B) [24]. Four NTD
densities could be assigned and shown in up configurations, and they are rendered into
slightly different orientations in the azimuthal direction along the C6 pseudo-symmetrical
axis (Figure 2B). Only one p47UBX domain was found to fit into the density attached to
the up NTD (Figure 2B). We did not identify any high-order form of the p47 bound to
p97, and it is consistent with the previous finding that the p97 NTDs interfere with p47
Int. J. Mol. Sci. 2021, 22, 8079 6 of 21
oligomerization [51,57]. In addition, the flattened densities of the NTD of p97 and p47
are possible due to their dynamic and partially disordered nature, leading to the weak
scattering signals and limiting resolution of these components (Figure 2B and Figure S1D).
We also performed image classification in 3D, but the result did not yield high-resolution
densities for modeling the SEP or UBA domain of the p47 (Figure S1D). This observation
is also corroborated by a neural network data analysis [58], showing high variations in
the NTD and p47 densities (Figure 2C). The densities of D1 and D2 rings were invariable
across the reconstructions. Unlike the p97WT-p47 complex [51], the mutant NTD may be
too disordered or mobile to present a structural feature with the p47 factor to be resolved
by cryo-EM.
In this complex assembling, we did not supply any nucleotides in the purification
steps, and nucleotide was not detectable in the D1 and D2 nucleotide-binding sites of the
p97R155H dodecamer or the p97R155H-p47 cryo-EM density maps. This observation differs
from the previous study where ADP is always observed in the wild type p97 D1 ATPase,
even when the nucleotide was not supplied in the sample buffers [23,26,59–61]. It is the first
time that the full-length p97R155H disease mutant structure is revealed by single-particle
cryo-EM. One possibility could be that the nucleotide binding for the p97R155H mutant is
weak in the extremely low concentrations of nucleotides, so the densities of the nucleotides
were insufficient to be detected in the averages of the cryo-EM images. Since the previous
analyses were conducted using p97WT or truncated p97 mutants, it is likely that the R155H
mutation or the domain-domain interactions in the full-length p97R155H reduces the affinity
of the D1 domain for ADP [45,62]. Furthermore, because the ADP off-rate of the p97R155H
D1 ATPase is two-fold faster than that of the p97WT D1 ATPase and the nucleotide binding
in the D2 domain depends on the D1 nucleotide state, it indicates a high likelihood of the
ADP binding instability in D1 ATPase of the full-length p97R155H [62]. Apart from this,
the previous SPR experiments showed that the R155H mutation reduces the ADP-binding
affinity to p97 [61,63]. Thus, the p97R155H mutant is likely to be structurally stable when
the nucleotide-binding pockets are empty.
2.3. P97R155H Dodecamer Is Stabilized by the Two Oppositely Stacked D2 Rings
Our SEC profile and SDS-PAGE analysis showed that the dimeric p97R155H hexamers
do not bind p47 (Figure 1B,C). To elucidate how the two hexamers organize into a higher-
order complex, we built an atomic model along with the cryo-EM density map of the
p97R155H dodecamer (Figure S2). The two p97R155H hexamers are oppositely packed against
their D2 rings with a D6 symmetrical arrangement (Figures 2A and 3A). We did not find any
density assigned for the p47 cofactor, as corroborated with our biochemical characterization
and the Kd determination of the p97-p47 binding (Figure 1B–D and Figure 2A). Thus, this
suggests that the p47 cofactor does not access the p97R155H dodecamer.
The C-terminal tail of the p97 (residues Q764 to G806) that interacts with the VCP
cofactors was previously reported as flexible and has not previously been structurally re-
solved for a full-length p97R155H mutant [19,64,65]. The crystal structure of the C-terminus
up to P774 of an engineered p97 variant has also been determined, but at a weak signal
level [56]. This is because in our p97R155H dodecamer, the C-terminal tail is sandwiched
by the two hexameric D2 rings, limiting its mobility and allowing visualization of high-
resolution details (Figure 3A). Our cryo-EM density map of the p97R155H dodecamer was
able to show an apparent density of the partial C-terminal tail (residues Q764 to F773)
(Figure 3A). The C-terminal tail points away from the pore center, interacting with another
C-terminal tail of the opposite neighbor to stabilize the packing of the two p97R155H hex-
amers (Figure 3B). Packing occurs via largely polar-polar interactions between the D2 α
helices and a hydrogen-bonding network of the C-terminal residues (D749, E756, Q760,
Q764, and R766) (Figure 3B). π-stacking forces between the aromatic side chains of the
C-terminal tails and the D2 α helices (F674, F682, F768, F771 and F773) also contribute to
the packing of the two p97R155H hexamers.
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p97CB-5083, respectively. Blue rectangles highlight conformational changes in the D1 helix-turn-helix
motif. The direction of the D2 movement upon ATPγS binding is shown in dots and an arrow.
2.4. Nucleotide Binding Destabilizes the p97R155H Dodecameric Formation
We did not find nucleotide binding in the p97R155H dodecamer structure, which
occupies about 39.1% of the population (Figure 1B,C and Figure S1). In contrast, p97WT
is always associated with ADP in the D1 ATPase and has a trace amount of dodecameric
form [19]. This could be possible because the nucleotide binding affects p97 oligomerization.
We would like to test whether the nucleotide in the solution affects the dodecameric
formation. We then mutated p97R155H on the Walker A motif of the D1 (K251R) or D2
(K524R) ATPase to disrupt the nucleotide binding. The Walker A mutants do not bind
any nucleotides nor perform the function. These double mutants were then imaged
using negative-stain electron microscopy (EM) for single-particle image analysis. 2D class
averages of these mutants showed that the ratios of the dodecamer to hexamer are 6.94:1
and 6.69:1 for p97R155H-K251R and p97R155H-K524R, respectively (Figure S3). Compared to
the above cryo-EM analysis of the p97R155H-p47 assembling, the ratios of the p97R155H
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dodecamer in D1 and D2 Walker A mutants increase 10.8 and 10.4 times, respectively.
This suggests that the p97R155H dodecamer is stable when it does not bind nucleotides.
Moreover, the double mutants lack ATPase activity, suggesting that the dodecameric
p97R155H is likely to represent an inactive state.
2.5. P97R155H Dodecamer Is Likely to Be an Inactive Form
To compare the monomeric structure of the p97R155H dodecamer with others, we su-
perimposed our structure with p97WT in ADP or ATPγS bound state and a CB-5083-bound
p97 (PDB codes: 5FTK (ADP), 5FTN (ATPγS), and 6MCK (CB-5083)) (Figure 3C) [37,54].
The superposition of p97R155H and p97|ATPγS revealed a downward rigid-body movement
of the D2 domain, which may be induced by the torsional change of the D1-D2 linker
(Figure 3C). Another significant structural change occurs in the C-terminal tail conforma-
tion. The C-terminal tail of the p97|ATPγS points to the pore center, which is in the opposite
direction, against that of the p97R155H dodecamer (Figure 3C). R766 on the C-terminal tail
has been found to interact with the γ-phosphate of the D2-bound nucleotide directly [56].
Because the C-terminal tail of the p97R155H dodecamer extends outwards from the pore cen-
ter and away from the D2 nucleotide-binding site, it is impossible to stabilize the nucleotide
binding. The D1 helix-turn-helix (HTH) motif (410–445) of the p97R155H dodecamer differs
from that of the p97|ADP, where the HTH motif interacts with the NTD and stabilizes it in
the down configuration (Figure 3C). However, the HTH motif in the p97R155H seems to not
interact with the NTD, allowing NTD to be less spatially restricted in the up configuration.
Although the NTD densities were resolved in low resolutions partly due to its mobility,
the NTD densities in low χontours (2.4σ) could still be identified in the up configuration
(Figure S1D).
CB-5083 is a highly selective D2 ATP-competitive inhibitor on p97 ATPase, and the
packing of the dimeric hexamers was also found in the crystal structure of the NTD-
truncated p97 with CB-5083 [54]. Based on these superpositions, the structure of the
p97R155H dodecamer more closely resembles p97|CB-5083 (RMSD 0.747 Å) than p97|ADP
(RMSD 0.919 Å) or p97|ATPγS (RMSD 1.127 Å) (Figure 3C). The crystal structure is con-
sistent with our dodecamer structure, suggesting that the p97R155H dodecamer could be
functionally equivalent to the inhibited p97 with CB-5083 (Figure 3C) [54].
2.6. Nucleotide Binding Influences the p47 Binding onto p97R155H
The nucleotide-bound state of the p97WT D1 domain affects the D2 ATPase activity and
influences the binding of the p47 cofactor [2,62]. In addition, p47 has a differential influence
on the D1 and D2 ATPase functions of wild-type and p97 mutants [45]. To uncover how
nucleotide binding modulates p47 binding to the p97R155H mutant, we assembled the
complexes in the presence of ADP or ATPγS and biochemically analyzed the resulting
complexes. ATPγS was used to mimic the ATP-bound site since it cannot be hydrolyzed
when bound to the nucleotide-binding site. The SEC profiles of the two assemblies in the
presence of ADP (p97R155H|ADP-p47) and ATPγS (p97R155H|ATPγS-p47) were similar, and
the peaks suggested a uniform distribution for both complexes (Figure S4A). SDS-PAGE
gel analyses verified the peak fractions containing p97R155H and p47 (Figure S4B).
We then collected the peak fractions and froze the samples for cryo-EM structural
analysis (Figures S5 and S6). Although no leading fraction was observed in the SEC profile
of the p97R155H|ADP-p47, a small fraction of the p97R155H dodecamers were identified in
the 2D image class averages (Figure S5). After 3D classification, the number of particle
images representing the p97R155H dodecamer was only 2219 (1.37%) among an overall
162,269 particle images. Like the 3D reconstruction of the p97R155H without nucleotides,
the dodecamer does not show any sign of bound nucleotide or p47 cofactor. However,
the p97R155H|ATPγS-p47 image dataset did not have the p97R155H dodecameric population,
suggesting that p97R155H dodecamer does not form in the presence of ATPγS (Figure S6).
Thus, these suggest that the nucleotide presence, particularly ATPγS, favors the dissociation
of the p97R155H dodecamer into hexamers. Furthermore, because the ATPase activity of
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the p97R155H is higher than p97WT [3,19,42,45,61,66] but the p97R155H dodecamer does not
interact with nucleotides, it is very likely that the increased activity of the p97R155H is
contributed from the functional hexamers, rather than dodecamers.
We calculated the 3D reconstructions of the p97R155H|ADP-p47 and p97R155H|ATPγS-
p47 complexes at 4.50 Å and 4.23 Å resolution, respectively (Figures S5 and S6). Cryo-EM
densities of the nucleotide can be identified in both the D1 and D2 nucleotide-binding
pockets of the p97R155H|ATPγS-p47 density (Figure S7). Unlike the p97R155H-p47 and
p97R155H|ATPγS-p47 densities, the p97R155H|ADP-p47 density map showed a heterogeneous
distribution of NTD orientations (Figure S8A). An NTD density with bound p47UBX domain
was identified (1.0σ), located at the highest height among all the other NTDs (Figure S8B).
The tilting angles and heights of the NTDs relative to the ring plane varied sequentially
(Figure S8B). This observation of the high structural variabilities is consistent with the deep
coordinate neural network analysis (Figure S9).
For the p97R155H|ATPγS-p47 complex, four NTDs and two p47UBX structures can be
assigned to the cryo-EM density, and the unassigned two NTD densities were fragmented
(Figure 4A). The four up NTD are consistent with the crystal structure of the truncated N-
D1 domain of the p97R155H|ATPγS [26]. Like the p97R155H|ADP-p47 complex, the densities
of NTDs and p47 were highly variable, but those for D1 and D2 domains were almost
invariant, as shown in the local resolution estimation (Figure S6D).
2.7. P47 Binding Impacts p97R155H Function via an Allosteric Effect on ATPases
Previous functional analyses demonstrated that cofactor binding or NTD mutation
alters p97 ATPase function, mainly the D2 ATPase [42,45]. However, the NTD is far away
from the nucleotide-binding pocket and how do NTDs allosterically regulate p97 ATPase
functions? Because D1 and D2 ATPase activities are correlated, one possibility is that
the NTD regulates ATPase functions via inter-domain or interprotomer communications
between these functional modules [42,67]. Because the cryo-EM density of p97R155H|ATPγS-
p47 allows us to visualize the side chains in its D1 and D2 domains, we compared it
with the model with p97WT|ATPγS structure (PDB code: 5FTN) [37]. We identified two
p47UBX bound onto the p97R155H NTDs, implying majority of the p97R155H particles bind
two p47 molecules. The superposition of the structures of the p47-bound p97R155H|ATPγS
and p97WT|ATPγS alone showed that the D2 domain slightly moves and most of the
critical residues in the nucleotide-binding pockets do not exhibit major conformational
changes (RMSD: 1.015 Å) (Figure 4B). However, the D2 R635, the D2 arginine finger, of
the p97R155H|ATPγS changes its conformation upon p47 binding, although the conforma-
tions of the D1 arginine fingers seem unchanged (Figure 4B). It is also known that the
arginine fingers extending from the neighbor protomer can affect the ATP hydrolysis
efficiency [3,68,69].
We would then like to test whether the D2 ATPase activity change is affected by
NTD mutation or p47 binding via the arginine fingers. We introduced two mutations of
the arginine fingers on R359A and R635A and measured the mutant ATPase activities
(Figure 4C). The p97R359A and p97R635A mutants have reduced activities compared to the
wild type (59% and 5%, respectively), and the mutation of the D2 R635 nearly abolished
the p97 ATPase activity, consistent with the previous findings [70]. We next prepared
the two double mutants, p97R155H-R359A and p97R155H-R635A, and the results showed that
both double mutants reduced p97R155H activities to 26% and 2.3%, respectively. Because
the p97R155H has a higher ATPase activity than p97WT (Figure 4C) [3,19,42,45,61,66], the
results showed that the increased p97R155H ATPase activity due to its R155H mutation
was diminished by the D1 and D2 arginine mutations. Both of the D1 and D2 arginine
fingers appear to affect the communications within p97 subunits for the R155H functional
enhancement. Thus, the gained ATPase activity from the R155H mutation of the NTD is
very likely to associate with functional arginine fingers.
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Next, we would like to know whether p47 impacts p97R155H function via arginine
fingers in the same man er as R155H mutation. As seen previously, upon binding to
p47, p97WT exhibits a biphasi response, but p97R155H does not exhibit the rebound
Phase 2 (Figure 4D) [45]. However, the D1 arginine finger mutants, p97R359A, l cked
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Phase 1 inhibition but showed significant activation in the later phase (1.9-fold), similar
to the D1 Walker B mutant (E305Q), which binds to nucleotide but does not perform the
catalysis (Figure 4D) [45]. Similar to p97R359A, the D2 arginine finger mutants, p97R635A,
showed a significant Phase 2 activation (3-fold), but different from the D2 Walker B mutant
(E578Q) (Figure 4E) [45]. These data indicate that upon p47 binding, the Phase 1 inhibition
of the p97WT associates with both D1 and D2 arginine fingers, but the Phase 2 activation is
mainly contributed by the D2 ATPase activity that associates with the D2 arginine finger
(Figure 4D,E). Thus, p47 likely impacts both wild type and p97R155H mutant via arginine
fingers, particular in Phase 2.
The responses of the double mutants showed both impacts from R155H mutation
and p47 binding. The p47 inhibitory regulation on the p97R155H was abolished for the two
double mutants, the p97R155H-R359A and p97R155H-R635A mutants (Figure 4C,D). Especially
for the p97R155H-R635A mutant for the D2 arginine finger, the curve is flat, implying that the
p47 binding has no impact on the ATP hydrolysis. Thus, this may indicate a functional
connection between p47 binding and the arginine fingers, R359 and R635, of the p97R155H
mutant. The structural superpositions showed that the change of the ATPase function
may result from the slight conformational changes of the arginine fingers (Figure 4A).
Thus, these findings suggest that the arginine fingers are critical for the p47-induced
communications between the NTD and ATPase domain.
In addition to the functional modulation of p47 via arginine fingers, we would like to
test whether the p47 binding is affected when the arginine finger is mutated. We fraction-
ated a mixture of p97R155H-R359A or p97R155H-R635A (1.67 µM in hexameric form) and p47
(80 µM in monomeric form) proteins in a gel-filtration column, using p97R155H as a positive
control (Figure S10). We found that the double mutant p97R155H-R359A and p97R155H-R635A
retained the ability to bind p47, eluting in the same fraction as the p97R155H-p47 com-
plex (Figure S10). We also determined the binding affinities, Kd, of the p47 to p97R155H,
p97R155H-R359A, and p97R155H-R635A as 132, 179, and 228 nM, respectively (Figure S11). Thus,
these results showed that the gained ATPase activities of the p97R155H-R635A from p97R155H
impacted by p47 may be partly due to weak p47 binding affinity to the p97R155H-R635A
double mutant (Figures 1 and 4E and Figure S11B). In addition, the impaired arginine
fingers reduce the p47 binding affinity to p97R155H, implying that the domain-domain
communications within p97 ATPase affect how p97 responds to cofactor binding.
3. Discussion
Single amino acid mutations in p97 have long been linked to diseases, including
IBMPFD and ALS [71], and these disease mutants alter the p97 ATPase activity and
cofactor binding on the NTDs [45]. Because the NTD is far away from the D2 ATPase,
where ATP hydrolysis mostly occurs, it is unclear how the NTD allosterically affects the
p97 ATPase function. The molecular mechanism underlying the disease is still unresolved
today. Our goal aims to understand (1) how NTD conformational change, such as up
and down configurations, connects to ATPase function, (2) the structural change of p97
ATPase caused by R155H mutation, and (3) how the mutant responds to p47 binding in the
context of a complete full-length complex. Here we conducted biochemical and structural
analyses to study potential pathological changes in the p97R155H mutant, the most prevalent
disease-linked mutation [53]. To our knowledge, our report reveals the first full-length
p97R155H mutant structures in dodecameric and hexameric forms, as well as the p97R155H-
p47 complex in different nucleotide states. Previous studies have placed less emphasis on
the p97R155H dodecamer. Our report found that the p97R155H dodecamer seems unstable
in the presence of nucleotides and insensitive to bind p47. Although we do not know if
the p97R155H dodecamer plays a physiological role in vivo or leads to IBMPFD disease, our
cryo-EM image analysis showed that this high order form can be stabilized in an aqueous
solution and occupies about 40%. We also found a possible connection for the p47 and
NTD regulation on ATPase function, likely arginine fingers, and the miscommunication
between these domains alters the normal ATPase activity. This may interfere with the
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ability of the p97 to carry out the p47-related function such as Golgi-membrane reassembly
or autophagy [30]. These new findings thus reveal how cellular functions may be so
profoundly impacted in the p97R155H mutant.
The formation of a p97WT dodecamer has been previously reported [47,56,72]. How-
ever, our SEC analysis did not show the dodecameric fraction in the wild-type assembly,
and the proportion of the p97WT dodecamer may be too low to be detected in our SEC
analysis (Figure 1B). Although it is not known whether the formation of the p97R155H
dodecamer occurs in vivo or whether it plays any role in a cell, the dodecamer at least can
be stably formed in the solution and likely in the cell as well. In addition, the structural
comparison of the CB-5083-bound structure [54] and its empty nucleotide-binding pockets
highly suggested the dodecameric form as an inactive state. The inactivation of the p97
dodecamer could be caused by its high-order organization, which may hinder the mobility
of the monomers, interfere with the hexameric ring to break, prevent hand-over-hand
movements and possibly, in turn, down-regulate normal p97 ATPase function during sub-
strate processing [31,32]. Only when the nucleotides are present, the p97R155H dodecamer
will dissociate into two functional hexamers with an elevated ATPase activity. However,
we have no information about why the R155H mutation favors the dodecameric formation.
One possible explanation would be that the dodecameric formation induced by R155H
mutation may keep p97 inactive while under the stress of the limited ATP concentrations
in the cell [54]. The definition of its functional role in vivo requires further investigations
using cell biological tools.
Our data showed that the p47 binding or NTD mutation affects the communications
between the functional modules of the full-length p97R155H ATPase in either an intra-
domain or an inter-domain manner or both. In addition, the affinity of p47 to p97R155H is
affected by the D1 or D2 ATPase activities. We also showed that either D1 or D2 arginine
finger mutation can affect the p47 binding affinity. These views might not be observed
using the truncated or incomplete p97 complexes to show the effects caused by domain
communications. The partial p97 ATPase may also lead to inconsistent observations on the
stoichiometry of the p97-p47 bindings. For example, the crystal structure of the p97N-D1-
p47UBX showed that two p47 UBX domains bind to two adjacent p97 monomers, while a
third is poorly resolved located away from those two bound NTDs [24]. However, this view
is not consistent with our observation from single-particle cryo-EM. Therefore, a complete
full-length complex will be required to provide a view of the interactions between overall
functional modules that are close to their native states.
Previous structural studies have revealed the interactions between p97WT and p47
proteins [24,51,57,73]. NMR (nuclear magnetic resonance) spectroscopic analysis of the
p97N-D1-L-p47 (residues 1-480 of p97) indicated a possible tripartite p47 binding mode [51].
This interaction involves the UBX and the C-terminal SHP of p47 binding to one p97 NTD,
while a third p47 N-terminal SHP domain binds the adjacent NTD of the p97. The up NTD
configurations allow organizing p47 in this arrangement, rather than down NTDs. On the
other hand, the p97R155H mutant, especially when bound to ATP, should interact with p47
cofactors followed by the proposed tripartite binding mode, since the NTDs are all in up
configuration [51,62]. However, our p97R155H-p47 complex structures indicate a disordered
or flexible structure of NTD or p47SHP domain, implying that p97 NTD mutant may either
interact with p47 more transiently or require a concerted motion on NTDs to adapt the
proposed binding mode [40,62]. In this sense, the oscillating up NTDs of the p97R155H|ADP
could easily access the p47 cofactors than the p97WT|ADP, which has all down NTDs [37].
This corroborates with the previous finding that the binding of p47 on the p97WT ATPase
in the presence of ADP is much weaker than those in the presence of ATP or the absence of
nucleotides [62]. However, the p47 binding for the p97R155H mutant is independent of the
nucleotide states [62].
Recent cryo-EM structures of the AAA+ ATPase with p47 cofactor or its homolog
showed an asymmetric arrangement of the hexameric structure [31,35]. These struc-
tures have shown the substrate binding in the central channel of the ATPase double
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ring [31,32,74]. However, we did not observe the same view in the structures of our com-
plexes or p97R155H ATPase alone. It is possible that the p47 binding alone or the R155H
NTD mutation cannot induce the domain movements and the presence of the substrate
seems to be required. Ufd1/Npl4 (UN) is one of the p97 cofactors that increase p97 un-
foldase activity [75,76]. The p97 disease mutant exhibited an elevated unfoldase activity
when binding to the UN cofactor and the substrate [38]. Although p47 seems not to
be involved in the unfoldase process, it may regulate p97 ATPase in a similar manner
for Golgi membrane reassembly or autophagy, which may not require substrate in the
pathway. The p97-p47-mediated membrane fusion requires the participation of VCIP135
(valosin-containing protein p97/p47 complex-interacting protein p135) and syntaxin-5
(Syn5) [77], which help in the coordination of ubiquitin transfer and ATP hydrolysis. These
cellular functions may utilize an action mode of p97 different from the ERAD (endoplasmic-
reticulum-associated protein degradation) process or require more proteins to initiate the
conformational changes to perform the function.
Here we propose a possible diseased mechanistic model for p97R155H regulation
(Figure 5). In the absence of nucleotides, the p97R155H mutant prefers to form a higher-
order p97R155H dodecamer, immobilizing C-terminal tails and prohibiting interaction of p47
cofactor with the NTD. When the nucleotide is present and binds to the enzyme mutant, the
p97R155H dodecamer dissociates into two functional hexamers, allowing cofactor binding
and performing ATP hydrolysis. The regulation of the p47 cofactor binding and functional
alteration by R155H mutation may induce a conformational change of the arginine fingers
and modulate the ATPase function. Our analyses suggest the importance of using a full-
length, rather than truncated, p97 for functional or structural characterization to gain a
complete view of the domain-domain communications within the p97 hexamer. To build on
our finding regarding dysregulation of interprotomer communication in p97R155H hexamer,
we expect the incorporation of additional physiological substrates for p97-p47 assembly
for the next critical step to understand the p97 pathological mechanism.
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4. Materials and Methods
4.1. Overexpression of the Wild Type p97, p97R155H Disease Mutant, and p47 Proteins
Plasmid constructs used for generating p97 and its mutants and p47 proteins are listed
in Table S1. Overexpression and purification of the p97 and its mutants and p47 followed
previous methods [61].
4.2. ATPase Activity Measurements
Detection of ATPase activity using Biomol Green reagent (Enzo Life Sciences, Farm-
ingdale, NY, USA) was performed as previously described with slight modifications [45].
To compare the ATPase activity of wild type and mutant p97 proteins, each purified protein
was diluted to a final monomer concentration of 25 nM in 50 µL ATPase assay buffer
(50 mM Tris (pH 7.4), 20 mM MgCl2, 1 mM EDTA, 0.5 mM TCEP, 0.01% Triton X-100 and
80 nM BSA). After adding 200 µM ATP, the reaction was carried out at room temperature
for optimal reaction times. 50 µL Biomol Green reagent (Enzo Life Sciences, Farmingdale,
NY, USA) was added to stop the reaction and the absorbance at 635 nm was measured
using a BioTek Synergy Neo 2 plate reader (BioTek, Winooski, VT, USA). The eleven-dose
titrations with p47 cofactor were performed by adding the varying amount of p47 protein
in ATPase buffer with p97. The results were calculated from five replicates using GraphPad
Prism 7.0.
4.3. P47 Binding Affinity Measurements
The binding affinity (Kd values) between p47 and p97WT or p97 mutants was de-
termined by measuring the temperature-related intensity change (TRIC) signals using a
Dianthus NT.23 instrument (Nano-Temper Technologies, München, Germany). p47 was
labeled with a RED-NHS dye using a Monolith Protein Labeling Kit RED-NHS second-
generation (Nano-Temper Technologies, CAT# LO-L011). The full-length wild type or
mutant p97 was titrated against 10 nM of p47-NHS in two-fold steps from 2.8 µM to
1.37 nM in 20 µL working buffer (20 mM HEPES (pH 7.4), 150 mM KCl, 1 mM MgCl2,
5% (w/v) glycerol, and 0.0025% (v/v) Tween 20). Assays were performed in a Dianthus
384-well plate and reproduced in three independent experiments. Data from the three
independent measurements were fitted using non-linear regression analysis in Prism 7.0.
4.4. Assembling p97-p47 Complexes
To assemble p47 with p97WT or p97 mutants, 1.67 µM p97 hexamer was mixed with
80 µM p47 for 10 min and fractionated in 20 mM HEPES (pH 7.4), 150 mM KCl, 1 mM
MgCl2, and 5% glycerol. Three different assemblies were prepared in the absence of
nucleotides and the presence of 100 µM ADP or ATPγS in the SEC elution buffer. The
mixture of the p97-p47 complex was loaded onto a Superdex 200 10/300 GL (GE Healthcare,
Chicago, IL, USA) for size-exclusion chromatography (SEC). When the samples were used
for cryo-EM analysis, 0.25% (v/v) glutaraldehyde (Electron Microscopy Sciences, Hatfield,
PA, USA) was applied for on-column cross-linking by following the previous method [78].
Peak fractions were characterized using SDS-PAGE, Western blotting, and negative-stain
electron microscopy (EM).
4.5. Negative-Stain Electron Microscopy for Single-Particle Analysis
The negatively stained specimens were prepared using the previous method [79].
0.01 mg/mL of the protein sample was used to applied onto a continuous carbon-coated
copper grid. The specimen was imaged using a Philips CM12 transmission electron micro-
scope (TEM) (80 keV) with a side-mounted CCD camera (Model 791, Gatan, Pleasanton,
CA, USA) or a FEI Tecnai TF20 TEM with a CCD camera.
For imaging the Walker A mutants, the specimens were imaged under a FEI Tec-
nai TF20 TEM, recording at a pixel size of 1.04 Å/pixel at the specimen level. 153 and
144 electron images were collected for p97R155H-K251R and p97R155H-K524R, respectively, and
imported into Relion (version 3.1-beta-commit-ca101f) [80] for image processing. 23,342
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and 23,020 particles of p97R155H-K251R and p97R155H-K524R were manually selected from
the electron images, respectively, and the two-dimensional (2D) class averages with an
assigned k of 50 were calculated. For the p97R155H-K251R dataset, the numbers of side views
for dodecamer and hexamer were 2173 and 313, respectively. For the p97R155H-K524R dataset,
the numbers are 2007 and 300, respectively.
4.6. Cryo-EM Data Collection
A holey-carbon C-flat grid (2/1 4C; Protochips, Morrisville, NC, USA) was glow-
discharged for 15 s using a Pelco easiGlow glow-discharge system (Ted Pella, Redding, CA,
USA). A 6 µL protein sample was applied to the pretreated grid, and the excess solution
was blotted using a filter paper (retention 20 µm) (Product #:47000-100, Ted Pella, Redding,
CA, USA). The grid specimen was quickly plunge frozen into liquid ethane using a Thermo
Fisher/FEI Vitrobot Mark IV automated freeze plunger (Thermo Fisher/FEI, Hillsborough,
OR, USA) for 6 s in a chamber with a humidity of 100%. Particle homogeneity and ice
backgrounds of the grid specimen were screened using a FEI Tecnai TF20 TEM. Grids with
thin ice and a homogenous particle dispersion were used for subsequent cryo-EM data
collection.
All the cryo-EM data in this report were collected at the Eyring Materials Center
(EMC) at Arizona State University (ASU) (Tempe, AZ, USA) using a Thermo Fisher/FEI
Titan Krios TEM (Thermo Fisher/FEI, Hillsborough, OR, USA) at an accelerating voltage of
300 keV. Cryo-EM movies were recorded using a Gatan K2 Summit direct electron detector
(DED) camera (Gatan, Pleasanton, CA, USA). Defocus range was set to −0.8 to −2.5 µm.
Nominal magnification was 48,077X, resulting in a physical pixel size of 1.04 Å/pixel at
the specimen level. The movie data was recorded at a counted rate of 2 e−/sub-pixel/sec
and a sub-frame rate of 200 msec in super-resolution mode. Total exposure was 6 s,
accumulating to a dosage of 44.4 e−/A2. The beam-image shift was applied to accelerate
data acquisition [81]. Data collection was automated using the customized SerialEM macros
(version 3.9) [82].
4.7. Image Processing
For the p97R155H-p47 assembly, 4223 collected movies were unpacked and gain-
normalized using Relion (version 3.1-beta-commit-ca101f) [80]. Image frames of a movie
were translationally registered and averaged with a dose-weighting scheme. The final
frame average was Fourier-cropped at the spatial frequency of 1.04 Å−1. The defocus
and astigmatism of the images were estimated using the CTFFIND4 program (version
4.1.13) [83]. A few particles were manually selected from the images, and their average
was then served as a searching template for the subsequent automated particle picking
in Relion [80]. 368,575 selected particle images were automatically selected, and the data
curation was completed using iterative 2D unsupervised classification. The classes with
discernible features were selected for ab initio volume generation using cryoSPARC soft-
ware (version 2.15) [84]. The two three-dimensional (3D) densities of a p97R155H dodecamer
and a p97R155H-p47 assembly were generated.
For particle images of the p97R155H dodecamer, one additional round of 3D classifi-
cation was performed to remove poorly aligned particle images. The selected 3D class
average was then refined against 64,252 experimental particle images by enforcing a D6
symmetry. The density was further improved using CTF refinement (fit of the defocus
and astigmatism per particle and estimation of beam tilt) [85] and Bayesian polishing [86]
procedures to a final resolution of 3.34 Å. The final map was sharpened using a b-factor of
−78.6 Å2.
For the p97R155H-p47 complex particle images, the consensus 3D volume of the
p97R155H-p47 complex was calculated at 4.30 Å resolution with a sharpened b-factor of
−125.7 Å2. The C6 symmetry was applied to further improve the densities of the D1 and D2
domains. The generated map reached a final resolution of 3.98 Å and was sharpened using
a b-factor of −139.3 Å2. The final resolutions of all the density maps were determined using
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the golden FSC criteria at 0.143 cutoff [87], and the local resolution estimations were per-
formed using the implementation in Relion software. The processing schematic is shown
in Figure S1. On the other hand, further 3D classification procedures with k = 6 or larger or
multiple hierarchical layers were attempted (Figure S1B). However, no major structural
differences between the generated class averages were discernible, and no improvements
were shown in the density quality in local regions of NTDs and p47 (Figure S1B).
For the p97R155H|ADP-p47 and p97R155H|ATPγS-p47 datasets, image processing was
generally conducted using cryoSPARC software (version 2.15) [84]. 3512 and 2796 movies
of the p97R155H|ADP-p47 and p97R155H|ATPγS-p47 were unpacked, gain-normalized and
imported into cryoSPARC, respectively. Frame registration and averaging were performed
using patch motion correction. Defocus and astigmatism parameters were estimated using
patch CTF estimation. Particle locations were automatically selected using the Topaz
program (version 0.2.3) [88]. For the p97R155H|ADP-p47 complex, 1,124,232 particle images
were selected and curated using iterative 2D unsupervised image classification. The classes
with discernible features were selected for ab initio volume generation. The two densities
of a p97R155H dodecamer and a p97R155H|ADP-p47 assembly were generated. 2219 and
160,050 particle images were used to calculate the final volumes of the p97R155H dodecamer
and the p97R155H|ADP-p47 complex, respectively. The two volumes were refined against
their experimental particle images and reached resolutions of 6.10 Å (p97R155H dodecamer)
and 4.50 Å (p97R155H|ADP-p47). Like the p97R155H-p47 dataset, further 3D classification did
not yield discernible features in the local regions for NTDs and p47. Processing schematic
and local resolution estimation are shown in Figure S5. For the 97R155H|ATPγS-p47 dataset,
we reconstruct the volume following the same procedure as above. Final 63,353 particle
images were used to reconstruct a 3D volume at 4.23 Å resolution, sharpened using a
b-factor of −77.6 Å2. Processing schematic and local resolution estimation are shown in
Figure S6.
Structural heterogeneity of the three p97R155H-p47 datasets was further analyzed using
a deep coordinate neural network by the cryoDRGN program (version 0.3) [58]. Before
latent encoding, the particle images were Fourier-cropped to a box size corresponding
to pixel sizes of 3.90 and 3.71 Å/pixel for p97R155H-p47 and p97R155H|ADP-p47 dataset,
respectively. For each group, an eight-dimensional latent variable model was trained for
25 epochs. The encoder and decoder architectures were three layers with 1024 nodes.
The latent encodings were visualized using a principal component factor plot or UMAP
(uniform manifold approximation and projection) representation [89]. After training, k-
means clustering with k = 20 was conducted on the latent encodings, and reconstructions
were calculated at the cluster centers using the decoder network.
4.8. Modeling
The previous p97 and p47 coordinates (PDB code: 5FTK and 1S3S) were used as the
templates for atomic modeling or molecular docking [24,37]. The templates were first
docked into individual cryo-EM densities using the ‘Fit in the Map’ function in UCSF
Chimera (version 1.14) [90]. The fitted model was manually rebuilt using Coot (version
0.9.1) [91] and then refined against the cryo-EM densities using the ‘phenix.real_space_refine’
program in Phenix software package (version 1.18.2-3874) [92]. Hydrogen atoms were
added using the ‘phenix.reduce’ program for the model refinement and removed after the
refinement. Secondary structure restraints were applied during the model refinement. The
refinement and validation statistics were listed in Table S3. The figures for the cryo-EM
density maps and atomic models were prepared using UCSF Chimera and ChimeraX
(version 0.91) [93].
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms22158079/s1. Figure S1: Cryo-EM analysis of the full-length p97R155H-p47 assembly in
the absence of nucleotides. Figure S2: Modelling of atomic coordinates in the cryo-EM densities of the
p97R155H dodecamer and p97R155H-p47 complexes in the absence of nucleotide. Figure S3: Single-
particle EM image analysis on the negatively stained Walker A mutants in the context of p97R155H.
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Figure S4: Biochemical characterization of the p97R155H|ADP-p47 and p97R155H|ATPγS-p47.
Figure S5: Cryo-EM structural analysis of the full-length p97R155H|ADP-p47 assembly. Figure S6:
Cryo-EM structural analysis of the full-length p97R155H|ATPγS-p47 assembly. Figure S7: Modelling
of atomic coordinates into the cryo-EM densities of p97R155H|ATPγS-p47 complexes. Figure S8:
Cryo-EM structure of the p97R155H|ADP-p47 complex. Figure S9: Deep coordinate neural network
analysis of the p97R155H|ADP-p47 single-particle cryo-EM images. Figure S10: Western blotting
analyses of the SEC-eluted fractions of the p97-p47 complexes. Figure S11: Determination of the
binding constant, Kd, for the interaction between p97 arginine finger mutants and p47 proteins.
Table S1: List of plasmids used for overexpression of p97 and p47 proteins. Table S2: Statistics of
single-particle cryo-EM structure determination on p97-p47 assembly.
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